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Abstract
Vascularized composite allotransplantation (VCA) has 
emerged as a useful reconstructive option for patients suf-
fering from major tissue defects and functional deficits. 
While the technical feasibility has been optimized and more 
than 130 VCAs have been performed during the last two de-
cades, hurdles such as acute and chronic allograft rejection, 
graft deterioration, and eventual functional impairment 
need to be addressed. Recently, chronic graft rejection and 
progressive failure have been linked to vascular alterations 
observed in the allografts. Graft vasculopathy (GV) may play 
a pivotal role in long-term graft deterioration. The under-
standing of the underlying pathophysiological processes 
and their initial triggers is of utmost importance in the pre-
vention, attenuation, and therapy of GV. While there are re-
ports on the etiology and development of GV in solid organ 
transplantation, there are limited data with respect to chron-
ic rejection and GV in the realm of VCA. Nevertheless, recent 
reports from long-term VCA recipients suggest that GV could 
truly jeopardize allografts in the follow-up evaluation. 
Chronic rejection and GV include different entities and might 
have different pathways in distinct organs. Herein, we re-
viewed the current literature on vascular changes during 
both acute and chronic allograft rejection, with a focus on 
their clinical and translational significance for VCA.
© 2019 S. Karger AG, Basel
Introduction
Over the last two decades, vascularized composite al-
lotransplantation (VCA) has evolved as a viable recon-
structive option for carefully selected patients with devas-
tating facial defects or of the upper extremities, and thus 
far, over 130 procedures have been performed worldwide 
[1]. Improvement in both surgical technique and immu-
nosuppressive regimen, largely adopted from solid organ 
transplantation (SOT), allowed to control acute rejection 
and guarantee short- and mid-term graft survival. The 
functional and immunological results in these patients are 
encouraging. Recently, chronic rejection and loss of vas-
cularized composite allografts (VCAGs) drew parallels to 
SOT with jeopardized long-term graft survival [2]. The 
half-life of transplanted solid organs ranges between 4 and 
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16 years or more [3]. Owing to the relatively small number 
of VCA patients as well as limited long-term patient fol-
low-up, it is difficult to predict the longevity of a VCAGs. 
Currently no precise definition of chronic rejection in 
VCA exists. Features of chronic rejection in VCA such as 
loss of adnexa, skin and muscle atrophy, fibrosis of deep 
tissue, formation of tertiary lymphoid follicles, nail chang-
es, or capillary thrombosis might be associated with vas-
cular alterations [4, 5]. Additionally, a handful of reports 
suggest that vascular smooth muscle cell (SMC) prolifera-
tion and endothelial deterioration resemble graft vascu-
lopathy (GV) and may play a crucial role in late graft loss, 
being a hallmark of chronic rejection in VCA [2, 6, 7]. GV 
is characterized by progressive concentric de novo myo-
intimal proliferation and luminal narrowing of predomi-
nantly arterial vessels (Fig.  1), resulting in subsequent 
graft ischemia, dysfunction, and eventual failure. Indeed, 
in heart transplantation, cardiac allograft vasculopathy 
(CAV) is one of the leading causes of graft loss and mor-
tality beyond the first year after transplantation [8].
Despite the high clinical relevance of GV, this topic 
remains insufficiently clarified and only a discrete body 
of knowledge is available, making it impossible to estab-
lish proper treatment options or prevention strategies to 
significantly ameliorate the long-term outcomes. It is im-
perative to understand the pathophysiology of GV so as 
to enable better prognosis and treatment of VCAG. The 
aim of this article is to review the current evidence and to 
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Fig. 1. Representative pictures of GV in a rodent model of vascularized composite allotransplantation. The top row 
depicts arteries with GV in both H&E (left) and Elastica van Gieson’s stain (right). These present myointimal pro-
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Reported Evidence for GV in Human Upper Extremity 
and Face Transplantation
We searched the PubMed database for all available re-
ports of histologically proven cases of GV in human up-
per extremity and face transplantation. The database was 
searched from September 23, 1998 (date of the first hu-
man hand transplantation) to March 15, 2019 using the 
following keywords: “hand transplant,” “face transplant,” 
“vascularized composite allotransplantation,” and “graft 
vasculopathy.” To match and remove duplicates, the 
search was refined using the Boolean operators AND and 
OR. Reports in languages other than English were exclud-
ed. In order to provide a comprehensive review of the 
literature, the relevant full-text reports together with as-
sociated references were profoundly scanned for infor-
mation regarding putative mechanisms, experimental 
models, and clinical management of GV in upper extrem-
ity and face transplantation.
As of March 2019, a retrospective study by Ng et al. [9] 
reported 11 GV cases (Table 1): 9 patients having upper 
extremity allografts and 2 patients having face allografts. 
Strikingly, more than half of the patients (6/11) who were 
diagnosed with GV eventually ended up losing their al-
lograft (Table 1). Challenging enough, GV appears not to 
always correlate with clinical skin changes, making early 
diagnosis difficult. One Louisville patient (No. 4, Table 1) 
lost his allograft as early as 9 months after transplantation 
due to an aggressive course of GV, but in absence of any 
chronic skin changes [7]. Other than that, 2 other VCA 
recipients (No. 3 and No. 10, Table 1) showed evidence of 
allograft fibrosis and functional impairment despite min-
imal GV [10, 11]. This is also in accordance with the Bos-
ton face transplantation experience. Indeed, chronic re-
jection was recognized in 3 out of 7 VCA recipients, but 
mostly limited to sclerotic skin changes and adnexal atro-
phy with no clear evidence of GV [12]. Of importance, the 
incidence of GV in human VCA in the present literature 
might be underestimated, for instance because of lack of 
reporting or challenges in the diagnosis of GV.
Potential Mechanisms of Vasculopathy in VCA
Numerous immunological and nonimmunological 
factors and pathways have been the focus of research for 
their contribution to GV, depicting it as a complex and 
multifactorial process. The pathogenesis has been exten-
sively studied in SOT, especially in cardiac transplanta-
tion, although the mechanism is not yet completely un-
derstood [13, 14]. However, several distinguishable pro-
cesses have been identified and are summarized in Figure 
2.
Disruption of Vascular Homeostasis
Vascular homeostasis is maintained by synergistic reg-
ulation between blood flow and the vascular endotheli-
um. The pre- and perioperative procedures during trans-
plantation disrupt this synergy, thereby initiating vascu-
lopathy within the graft. In the perioperative period, 
vascular injury is caused by an absence of graft perfusion 
as in deceased donors and relates to delayed graft func-
tion and poor graft survival when compared to perfused 
grafts obtained from brain-dead donors [15, 16]. Simul-
taneously, the endothelium becomes dysfunctional, trig-
gering an imbalance in the production of vasoactive fac-
tors. The occurrence and effect of this imbalance has been 
studied in SOT, but not yet in VCA. In liver transplanta-
tion, increased angiotensin II and decreased bradykinin 
levels were detected during the anhepatic phase [17]. An 
increase in the expression of endothelin-1 in ex vivo per-
fused lungs was shown to correlate with poor transplanta-
tion outcome [18]. Endothelial dysfunction is also char-
acterized by changes in the endothelium phenotype by 
overexpression of adhesion molecules switching to a pro-
inflammatory state that leads to GV as shown in aortic 
transplantation [19].
An added feature of endothelial dysfunction during 
transplantation that directly reflects GV is accumulation 
of glycocalyx and lipids in the intima and media as shown 
in SOT [20]. Increased accumulation of the glycocalyx 
directly contributes to thickening of the intima in GV. 
Lipids are entrapped in this dense network of accumu-
lated glycocalyx, resulting in vascular hyperlipidemia. 
Several other factors also contribute to hyperlipidemia 
that collectively progresses into atherosclerosis and GV 
[21, 22]. The evidence of atherosclerosis contributing to 
GV is based on (1) histological similarities between ath-
erosclerosis and GV and (2) therapeutic outcomes by the 
use of statins during transplantation. Both involve mac-
rophage and T cell infiltration of the vascular wall, trig-
gering intimal proliferation, with the exception of lipid-
laden foam cells, which are more typical for atheroscle-
rotic plaques. More specifically, low-density lipoproteins 
are associated with macrophage-like foam cells in athero-
sclerosis [23] and HLA antigens expressed mainly on the 
endothelial surface in GV [24].
With regard to therapeutic outcomes, a pooled analy-
sis confirmed that statins improve survival in heart trans-
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[25]. Administration of statins reduced the 1-year mor-
tality in heart transplantation by over 11% according to a 
meta-analysis by Mehra and Raval [26]. Furthermore, Yi 
et al. [27] reported amelioration of human allograft arte-
rial injury by statins in an animal model. In this study, 
C.B.-17 severe combined immunodeficiency-beige mice 
received human artery segments as aortic interposition 
grafts. Upon inoculation with allogeneic human periph-
eral blood mononuclear cells, the occurrence of GV was 
reduced by simvastatin or atorvastatin, correlating to a 
decrease of graft-infiltrating CD3+ T cells. Another study 
showed the immunosuppressive effect of statin in hetero-
topic limb allografts in rats via attenuation of T cell acti-
vation and proliferation [28]. It is thus clear that statins 
have both lipid-lowering and immunomodulatory effects 
in allografts. Therefore, evidence for the contribution of 
atherosclerosis to GV in VCA may be important, but the 
mechanism is not clear and requires further study.
In SOT patients, the vasculature is in an activated, hy-
percoagulable state. The etiology for this condition is 
multifactorial including age, drugs, surgical procedure, 
diabetes mellitus, vascular anomalies, and heredity [29]. 
In case of cardiac transplantation hypercoagulable vascu-
lature, defined by fibrin deposits and binding of anti-
thrombin, has been shown to be directly associated with 
initiation and progression of vasculopathy [30]. Although 
the first clinical evidence from VCA is emerging [31], the 
occurrence and significance of hypercoagulable vascula-
ture in VCAGs needs to be further established.
Ischemia-Reperfusion Injury
Ischemia-reperfusion injury (IRI) is a key issue in peri-
operative graft injury and of great importance. Ischemia 
is the absence of blood flow and reperfusion, the recom-
mencement of blood perfusion into previously ischemic 
tissue are two phases with distinct pathophysiology. In 
transplantation, ischemia starts with termination of do-
nor circulation (warm ischemia), continues during peri-
operative graft cold storage (cold ischemia), and ends 
with reperfusion after unclamping. The recovery and 
handling of donor tissue has a huge impact on the integ-
rity of allograft vessels. In this manner, the transplant 
procedure itself, irrespective of immunological HLA-
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Fig. 2. An overview of possible mechanisms contributing to graft 
vasculopathy. CNI, calcineurin inhibitor; DAMPs, damage-asso-
ciated molecular patterns; ICAM-1, intercellular adhesion mole-
cule 1; MHC, major histocompatibility complex; NK, natural kill-
er; PECAM-1, platelet endothelial cell adhesion molecule 1; PRRs, 
pattern recognition receptors; VCAM-1, vascular cell adhesion 
molecule 1.
Vasculopathy in Vascularized Composite 
Allotransplantation
169J Vasc Res 2019;56:163–180
DOI: 10.1159/000500958
contribute to deterioration and dysfunction [32]. Yi et al. 
[33] demonstrated that IRI, as part of perioperative in-
jury, is sufficient to induce GV, which is further boosted 
by adaptive immune responses.
The mechanisms of IRI, including the generation of 
reactive oxygen species, initiation of inflammation and 
coagulation pathways, endothelial activation and dam-
age, and their detrimental effects during transplantation, 
have been previously summarized for both SOT and VCA 
[34, 35]. IRI correlates with the development of trans-
plant vasculopathy in SOT [36, 37]. Accordingly, it is 
plausible that IRI may trigger chronic rejection and pro-
mote GV in VCA as well. In mouse orthotopic hindlimb 
transplantation, prolonged cold ischemia led to increased 
vascular endothelial injury, vascular alteration, and even-
tual organ dysfunction [38]. In a rat model of vascularized 
allogenic skin flaps, Shimizu et al. [39] found that pro-
longed ischemia of 6 h duration caused earlier and stron-
ger episodes of acute rejection than 1 h of ischemia under 
immunosuppression with cyclosporine A. This is in line 
with another study where vascularized skin flaps were 
transplanted from Wistar Kyoto to Fisher 344 rats after 1 
or 3 h of ischemia, with no immunosuppression, reveal-
ing higher rejection grade scores in skin/muscle biopsies 
of animals with prolonged graft ischemia time [40]. These 
experimental findings correlating rejection to prolonged 
ischemia time and IRI need clinical verification. Owing to 
the low numbers in VCA, this aim might be difficult to 
accomplish. Nevertheless, Herzberg et al. [41] attributed 
prolonged ischemia time of > 9 h in their bilateral hand 
transplant patient to inferior intrinsic muscle function re-
covery compared to an Austrian bilateral hand transplant 
patient with only 3 h of ischemia. Landin et al. [42] sus-
pected perioperative IRI to be a cause of later flexor con-
tracture in a forearm transplant recipient. Caterson et al. 
[43] did not find a correlation between ischemia time and 
the frequency of rejection in their face transplant series. 
Thus far, reports from clinical VCA are more of a specu-
lative nature for being singular cases or small series.
These circumstances stress the importance of peri- 
and postoperative monitoring and quantification of isch-
emic injury in VCA. Immediate pathological changes af-
ter transplantation due to IRI could be assessed with bi-
opsies over 24–48 h after ischemia [44]. Outcome 
indicators such as circulating and tissue lactate, nitroblue 
tetrazolium, tissue myeloperoxidase, CD31, and wet-to-
dry weight ratio could be taken into account, but may lack 
specificity [38, 45–48]. Systemic effects of IRI could be 
measured by assessment of various cytokines and chemo-
kines, including TNF-α, IFN-γ, IL-6, and VEGF, but are 
currently not the standard [49]. It remains challenging to 
fully understand the contribution of IRI versus peri-/
postoperative inflammation or immune response in gen-
eral to the changes seen in the abovementioned markers 
or histological signs.
Currently much effort is undertaken to establish novel 
preservation protocols for both preservation/perfusion 
fluids [50–55] and ex vivo machine perfusion [56–62] to 
reduce or avoid IRI. While some preservation solutions 
were shown to be favorable compared to others in SOT, 
this needs yet to be identified in VCA. Pursuing this goal, 
two experimental studies of syngeneic rat hindlimb trans-
plantation compared the effects of different preservation 
solutions (saline, University of Wisconsin solution, HTK, 
HTK-N, TiProtec) and cold ischemia time (ranging from 
2 to 30 h) on tissue injury [63, 64]. Interestingly, no clear 
superiority of any of the studied preservation solutions 
could be demonstrated, and the authors concluded that 
the length of cold ischemia time is the most significant 
factor determining IRI in VCA [63].
One future direction might aim at implementing and 
customizing preservation fluids with addition of supple-
ments [65, 66], improved oxygenation [67], combined to 
controlled hypo- and (sub)normothermic machine per-
fusion, to reduce ischemic injury during preservation and 
thus improve immunological and functional outcomes. 
Moreover, improved preservation strategies would allow 
prolonged bridging time from donor to recipient and in-
crease allograft availability and allocation potential.
Cell-Mediated Rejection
Cell-mediated rejection is the predominant mecha-
nism during acute rejection episodes as suggested by peri-
vascular CD3/CD4-positive infiltrates in histological 
specimens of VCAGs [68]. In acute cell-mediated rejec-
tion, the effector T cells execute their function mainly by 
two mechanisms. While CD8-positive T cells mediate cy-
tolysis after binding of peptides to major histocompatibil-
ity complex (MHC) class I molecules, CD4-positive effec-
tor T cells respond to the binding of antigens to MHC 
class II molecules [69]. Endothelial cells are the primary 
target of effector T cells in the vasculature as they present 
high levels of class I and II HLA molecules, compared to 
graft SMCs which express minimal levels of HLA com-
plexes [70, 71].
Although T cell function has been extensively investi-
gated, their involvement and contribution in the patho-
genesis of vascular changes in VCA remains unclear. 
Contrary to the mechanisms mentioned above, a report 
by Lian et al. [72] suggests that donor effector T cells were 
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responsible for tissue damage in the face of VCAG. The 
targets of donor T cells and their role in vascular injury 
should therefore be further addressed. Other than that, 
there is also evidence indicating that chronic CAV can be 
mediated by B cells independently of antibody produc-
tion, as found by Zeng et al. [73] in a murine model.
Immunosuppressive drugs such as calcineurin inhibi-
tors, mTOR inhibitors, mycophenolate mofetil (MMF), 
or steroids target T cell function and can thus efficiently 
control acute T cell-mediated rejection. Nevertheless, GV 
can develop under conventional immunosuppression 
and clinical unapparent rejection in both SOT and VCA 
and is a major cause of late progressive graft failure [2]. 
This suggests that current immunosuppressive drug reg-
imens are insufficient to prevent long-term vascular dam-
age, and additional mechanisms may be involved.
Antibody-Mediated Rejection
In SOT, vascular rejection is traditionally associated 
with cell-mediated rejection, but the humoral involve-
ment is increasingly recognized to be part of this process 
[74, 75]. Despite most rejection episodes being cell-medi-
ated in VCA, cases of acute antibody-mediated rejection 
(AMR) in face- or hand-transplanted patients have also 
been reported [76, 77]. During AMR, donor-specific an-
tibodies (DSA) trigger rejection [78]. DSA typically acti-
vate complement deposition in the endothelium (C4d) 
via the classical pathway [76, 79, 80], even though com-
plement-deposition free rejection has been reported [81]. 
AMR usually manifests as chronic rejection and slow, 
progressive graft deterioration, favoring development of 
GV. Indeed, in renal or cardiac transplantation, AMR is 
believed to drive chronic rejection and promote GV [82, 
83]. A supposed mechanism of action is complement-
mediated injury of the allograft vessels and persistent or 
progressive vascular inflammation with intimal hyper-
plasia [84, 85]. Additional evidence also suggests that 
DSA binding direct to endothelial cells can lead to GV, 
bypassing activation of the complement system [86]. 
However, the exact mechanism by which these antibod-
ies, being more prone to endothelial cells than SMCs, pro-
mote proliferation of the latter and migration into the 
hyperplastic intima is not yet clear [13]. AMR may be 
more likely in the presence of C4d deposition and occur-
rence of DSA [87]. However, graft complement deposi-
tion may also occur independently from DSA, e.g., 
through binding of autoantibodies after IRI [88, 89]. Re-
ports from both SOT and VCA suggest that also non-
HLA-related antibodies, like those directed against an-
giotensin II type 1 receptor, may play a role in vasculopa-
thy [90–93]. Given these aspects, the accurate diagnosis 
of AMR remains a challenge [94, 95].
Indeed, in clinical VCA, the diagnostic criteria for 
AMR are not included in the current Banff classification 
[4]. Therefore, the role of AMR in chronic rejection and 
GV still has to be clarified. The first face transplant pa-
tient (No. 11, Table 1) who partially lost the allograft as 
late as 10 years after transplantation developed progres-
sively increasing de novo class II DSA, C4d deposits in the 
endothelium, as well as GV [2]. On the other hand, expe-
rience with upper extremity transplantation from the 
same group showed that GV can occur in patients with 
low-level transient DSA (No. 8, Table 1) [96] and even 
without DSA (No. 7, Table 1) [97]. Additionally, Kaufman 
et al. [7] reported on 2 patients with severe GV. In the first 
case, strong progressive vasculopathy eventually resulted 
in graft loss 9 months postoperatively (No. 4, Table 1). No 
DSA were detected, nor did the explanted tissue show any 
evidence of C4d deposition. Strikingly, DSA were detect-
ed 3 days after hand amputation and cessation of immu-
nosuppression. The second patient (No. 6, Table 1) with 
severe GV showed C4d deposits in deep vessels, but no 
circulating DSA could be detected [7]. According to a fol-
low-up report from the same center, one patient (No. 5, 
Table 1) developed de novo class II DSA 6 years after 
transplantation and ultimately lost his allograft due to GV 
3 years later [10]. Interestingly, in a bilateral hand trans-
plant patient in Austria, acute AMR due to de novo DSA 
was reported by Weissenbacher et al. [77]. The same 
group also added costimulatory blockade drug belatacept 
into maintenance immunosuppression of 4 upper ex-
tremity transplant recipients [98]. Unfortunately, in 1 pa-
tient (No. 9, Table 1) with high levels of class II DSA at 
the time of belatacept initiation, acute rejection occurred 
and eventually led to allograft amputation. The biopsies 
from the amputated hand revealed severe GV in associa-
tion with positive C4d stain [98].
In summary, 100% of patients with GV and detectable 
class II DSA lost their allograft within 2.5–5 years from 
first detection of class II DSA (Table 1). Occurrence of 
GV in absence of DSA in some other patients, however, 
suggests that both cell- and antibody-mediated mecha-
nisms are involved in the pathophysiology of GV.
Repeated and Subclinical Rejection
The relationship between number of acute rejection 
episodes, development of chronic rejection, and GV is 
not fully understood to date. Reports from experimental 
models of rat and nonhuman primate (NHP) VCAs 
showed that repetitive acute rejection combined with 
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subtherapeutic treatment [99], reduction of maintenance 
immunosuppression [100], or complete discontinuation 
of immunosuppressive drugs [101] can induce vascular 
changes resembling those of GV. A couple of reports in 
clinical VCA suggest a similar course in patients with de-
crease or discontinuation of immunosuppression due to 
nonadherence [6, 97, 102] or complications [2, 11]. On 
the other hand, there is also evidence that GV can develop 
in patients compliant with the immunosuppressive regi-
men [7, 103].
Alternative Pathways
Immunosuppression is currently required to prevent 
graft rejection in clinical VCA recipients, and serious ad-
verse effects should be considered. In the literature the 
focus is on metabolic, infectious, or malignant adverse 
effects of immunosuppressive regimen in VCA [2, 104, 
105], but the pathophysiological link to GV has not yet 
been studied.
A multitude of induction and maintenance immuno-
suppression protocols is reported in the clinical VCA lit-
erature. The most commonly used induction agent is an-
tithymocyte globulin. Alternative induction regimens 
have been reported, e.g., the use of basiliximab [106, 107], 
alemtuzumab [7, 108, 109], or rituximab [110]. Other in-
duction strategies included allograft preradiation [106], 
extracorporeal photopheresis [104], plasmapheresis with 
intravenous immunoglobulin in a sensitized recipient 
[76], or infusion of donor-derived bone marrow cells 
[109, 111]. Maintenance immunosuppression usually 
consists of triple therapy with tacrolimus, MMF, and ste-
roids. Tacrolimus target levels have been reported some-
where between 6 and 15 ng/mL [109, 112, 113], and MMF 
daily doses have ranged from 720 mg [114] to 3 g [111]. 
Furthermore, attempts to withdraw MMF [115] or ste-
roids [7, 116] as well as tacrolimus monotherapy [109] 
have been described. Progressive decrease of renal func-
tion has led to conversion of tacrolimus to mTOR inhib-
itor and/or belatacept in a few upper extremity and face 
transplant recipients [98, 113, 117, 118]. As of now, it re-
mains unclear which abovementioned induction and 
maintenance protocols are beneficial against the develop-
ment of GV.
Endothelial dysfunction in renal transplantation might 
be related to cyclosporine A [119] and tacrolimus medi-
cation [120]. TLR4 signaling in endothelial cells may play 
a role in this process according to Rodrigues-Diez et al. 
[121]. Indeed, all patients in Table 1 received tacrolimus, 
but evidence for pathophysiological association with GV 
is difficult to prove owing the limited number of cases. 
The same accounts for steroid-sparing immunosuppres-
sion or use of mTOR inhibitors, since it appears that GV 
can develop under any currently used immunosuppres-
sive regimen.
Another potential trigger for vascular alterations in al-
lografts might be of infectious origin, despite weak evi-
dence. In atherosclerosis, concomitant bacterial infection 
such as gastritis, gingivitis, or respiratory infection might 
influence disease development [122]. Moreover, cyto-
megalovirus infection is considered a risk factor for CAV 
[123]; however, the exact mechanism has not yet been 
clarified.
Diagnosis and Monitoring of Vascular Alterations in 
VCA
Histopathological Markers
Markers for the detection or prediction of vascular 
changes or acute/chronic rejection are of great interest for 
both VCA and SOT (Table 2) [124, 125]. Although a de-
cent amount of research has been carried out in SOT, lit-
tle is known, and there is a paucity of knowledge for VCA. 
Hautz et al. [68] provided an extensive histopathological 
analysis for different markers during rejection in hand 
transplant recipients. Interestingly, many of these mark-
ers were directly or indirectly associated with GV: cellular 
infiltration included CD3, CD4, CD8, CD20, CD68, and 
HLA class II-DR expression in tissue samples; AMR was 
associated with CD20 and C4d; IDO and Foxp3 were re-
garded as markers for tolerance; LFA-1, ICAM-1, E-se-
lectin, P-selectin, VE-cadherin, and Psoriasin were sum-
marized as adhesion molecules. Of these markers, CD68, 
Foxp3, and IDO expression as well as CD4/CD8 ratio cor-
related well with the grade of rejection. Moreover, lym-
phocyte adhesion molecules, especially ICAM-1 and E-
selectin, also strongly correlated with the severity of rejec-
tion. In this context, the role of CD68 as an adhesion 
molecule could also be taken into consideration, although 
its exact role remains unclear [126]. In a follow-up study 
of the same group, tissue specimens from NHP and rats 
were added to the histopathological assessment [127]. In 
this work, peripheral node addressin (PNAd) as a marker 
of lymphatic neoangiogenesis was evaluated during rejec-
tion. Its expression significantly increased in the intra-
graft endothelium upon rejection in human skin com-
pared to naïve skin and correlated with B and T lympho-
cyte infiltration and LFA-1 expression in the tissue. Of 
interest, PNAd expression was clearly higher in biopsies 
at 5 or more postoperative years compared to early fol-
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Table 2. Potential detection and monitoring of vascular alterations in experimental and clinical VCA
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low-up after transplantation. Earlier, PNAd had also been 
linked to lymphoid neoangiogenesis in tertiary lymphoid 
organs of murine cardiac transplantation [128]. An ad-
ditional marker helping in the detection of transplant vas-
culopathy might be alpha smooth muscle actin as it is 
linked to intimal SMC proliferation [129].
An inherent disadvantage of the abovementioned 
markers is the invasive nature of the tissue biopsy. In ad-
dition, allograft vessels can be concomitantly affected by 
different pathologies, and it might be difficult to differen-
tiate between inflammatory, infectious, and neoplastic 
dermatoses in skin biopsies of VCAGs [130]. Wolfram et 
al. suggest novel approaches to address this issue by using 
gene expression analysis [131] or computational model-
ing of cytokine profiles [132].
In summary, there are no predictive markers yet for 
transplant vasculopathy/chronic rejection in VCA.
Noninvasive Markers
Given the fact that detection of class II de novo DSA is 
almost inevitably associated with GV and allograft loss in 
VCA (Table 1) [2, 10, 98], regular monitoring of circulat-
ing MHC antibodies appears to be of utmost relevance. 
Indeed, a recent retrospective multicenter study revealed 
that from 44 analyzed upper extremity recipients, 14 
(32%) developed de novo DSA [133]. However, a strong 
correlation between DSA and graft survival could not be 
found, suggesting a relatively high variability between the 
involved centers with regard to antibody development as 
well as sampling differences [133].
Additional noninvasive markers are evaluated as alter-
natives to graft biopsies in the field of transplantation, 
with potential implications for VCA (Table 2). These 
might be based on gene expression profiling [134, 135], 
proteomic analysis [136, 137], cell-free DNA [138, 139], 
or B cell repertoire sequencing [140] analyzed from pe-
ripheral blood samples or skin patch tests. Other studies 
point out at the possibility of marker analysis from urine 
samples or even breath [141, 142]. Even though all of 
these markers might be promising, it is important to note 
that their sensitivity and specificity have not been as-
sessed in VCA yet.
Clinical Monitoring of GV
Conventional graft biopsy is associated with donor site 
morbidity and scarring, especially relevant in face trans-
plant recipients, or could even trigger episodes of acute 
rejection. While noninvasive markers are not established 
yet, noninvasive monitoring of rejection and vasculopa-
thy in VCAGs is desired.
To overcome this problem, noninvasive imaging tech-
niques are currently being evaluated in VCA recipients 
(Table 2) [7, 143]. Computed tomography and magnetic 
resonance angiography seem to fail the scope of monitor-
ing transplant vasculopathy owing to limited spatial reso-
lution and low sensitivity for early stages of the disease. 
Ultrasound biomicroscopy (UBM) might be a useful al-
ternative for this purpose. Indeed, a study by Kaufman et 
al. [7] provides the first report about the use of UBM for 
imaging and monitoring of transplant vasculopathy in 
larger and smaller arteries in clinical VCA. Interestingly, 
in the Louisville series of 6 hand transplant patients with 
follow-ups from 9 months to 12 years, all presented with 
some degree of vasculopathy [7]. However, the 2 subjects 
with the longest follow-up (> 10 years) showed the least 
vascular changes with minimal luminal occlusion [7]. 
UBM has also been evaluated as a diagnostic tool in a se-
ries of face transplant recipients, proving its applicability 
for repetitive postoperative vessel monitoring. Kueckel-
haus et al. [143] found that even if the intima was thicker 
in all sites in face transplant patients than healthy con-
trols, the ratio between intimal thickness of facial and ra-
dial arteries was similar in transplanted patients and con-
trols. To confirm UBM as a proper diagnostic tool for GV 
in face transplants, a long-term follow-up ideally includ-
ing tissue biopsies will have to clarify its sensitivity and 
reliability. UBM as a monitoring tool in VCA is in its in-
fancy, and to our best knowledge comparisons to vascular 
changes during other procedures than VCA such as re-
plantations or free tissue transfers are lacking.
In clinical heart transplantation, intravascular ultra-
sound is routinely used for the assessment of CAV and 
associated perivascular proliferation [144]. As further re-
finement of intravascular monitoring, attention is drawn 
to another interesting imaging technique called optical 
coherence tomography (OCT). This technique, in con-
trast to ultrasound, works with near-infrared electromag-
netic waves and provides the advantage of high-resolu-
tion quantitative vessel imaging [145]. It has been utilized 
to visualize initial vascular alterations of CAV heart trans-
plantation [146]. In VCA, the transdermal application of 
OCT could provide noninvasive monitoring of the vascu-
lature. Indeed, one group evaluated OCT for imaging of 
superficial temporal arteries by transdermal OCT in giant 
cell arteritis with mixed results for limited penetration 
depth [147]. Whether the actual depth of penetration is 
sufficient to image the vessels of interest in VCA needs 
therefore to be investigated.
The field of VCA could potentially benefit from sev-
eral other advanced imaging techniques. In a study by Zor 
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et al. [148], vascularized groin flaps were transplanted be-
tween Sprague-Dawley rats and noninvasively monitored 
for signs of acute rejection by the means of reflectance 
confocal microscopy, and a significant correlation be-
tween histopathological grades and reflectance confocal 
microscopy scores could be established. Multiphoton mi-
croscopy is another technique that enables three-dimen-
sional, sub-micrometer-resolved imaging of unstained 
living tissue, potentially filling the resolution gap between 
OCT and scanning electron microscopy [149]. This could 
have significant implications in clinical research, includ-
ing detection of vascular anatomy. Low depth of tissue 
penetration, device bulkiness, and immobility as well as 
high costs typically limit the use of such technologies 
[150].
Experimental Models of Vasculopathy in VCAGs
Experimental models of chronic rejection and GV are 
crucial for the understanding of these pathophysiological 
processes and development of preventive and therapeutic 
strategies. As mentioned above, three basic animal mod-
els of chronic rejection have been studied for this pur-
pose. In a rat hindlimb transplantation model, grafts un-
derwent repetitive cycles of acute rejection-remission, 
trying to arbitrarily imitate chronic rejection. Upon signs 
of acute rejection, cyclosporine A and dexamethasone 
were administered until remission and then discontin-
ued. The grafts showed significant myointimal prolifera-
tion at 90 days in H&E-stained specimens, resulting in 
concentric luminal occlusion and perivascular and mus-
cular fibrosis [99].
Mundinger et al. [100] used an NHP fibula flap model 
in mismatched cynomolgus macaques. The animals re-
ceived either initial high-dose tacrolimus monotherapy 
(n = 3) or low-dose tacrolimus with anti-CD28 costimu-
latory blocking antibody (n = 2). The tacrolimus dose was 
reduced to maintenance levels in both groups after 28 
days, and all animals reached the endpoint of 180 postop-
erative days. Histological analysis at endpoint revealed 
GV in both animals in the low-dose group; unfortunately, 
this was not investigated in the first group [100].
In another work from the same group, chronic rejec-
tion in an NHP heterotopic face transplant model was 
reported [101]. Five animals with long-term graft surviv-
al (> 200 days) and detectable macrochimerism were 
completely weaned of immunosuppression consisting of 
tacrolimus/MMF (n = 4) or tacrolimus/anti-CD28 co-
stimulatory blocking antibody (n = 1). All five grafts were 
rejected after immunosuppression withdrawal, and biop-
sies from all grafts revealed neointimal hyperplasia and 
arterial luminal narrowing consistent with vasculopathy 
[101]. As early biopsies were unavailable, it remains spec-
ulative whether the observed vascular changes were of 
acute or chronic origin.
Although the three abovementioned models are capa-
ble of producing vascular changes consistent with GV, it 
is questionable how appropriately these models reflect 
chronic rejection. In the first model, repetitive episodes 
of acute rejection resulted in GV, potentially reflecting 
the clinical VCA situation, with a majority of patients un-
dergoing multiple acute rejection episodes in the first 2 
years after transplantation. Long-term vascular changes 
in the NHP model may, however, better reflect chronic 
graft deterioration under subtherapeutic immunosup-
pression.
Further models for chronic rejection in VCA could be 
derived from established SOT models [151]. The Fisher 
to Lewis rat model is another interesting model of chron-
ic rejection in kidney transplantation [152]. Compared to 
the well-established Brown Norway to Lewis full mis-
match VCA model, the Fischer/Lewis model is a minor 
mismatch model with no need for immunosuppression. 
Similarly, taking advantage of minor genetic mismatches, 
the WF.1L/Lewis rat model could also be utilized in VCA. 
WF.1L is a congenic rat strain derived from backcrossing 
Lewis to Wistar Furth rats. In a study by Forbes et al. 
[153], hearts from WF.1L rats were transplanted into 
Lewis rats without the need for maintenance immuno-
suppression. While the grafts clinically showed no rejec-
tion and an indefinite survival, they developed vasculitis 
with myointimal thickening. Such models could be of 
high interest for experimental VCA with a focus on GV.
Potential Treatment Options and Perspectives
There are several potential novel therapeutic ap-
proaches that might reduce or mitigate chronic rejection 
and GV. First, drug-based induction and maintenance 
therapy is of particular interest. Costimulatory blockade 
can induce allograft tolerance and reduce GV in experi-
mental models of SOT [154–156]. In experimental VCA, 
reports of tolerance induction in small [157] and large 
[158] animals sound promising. However, clinical stud-
ies specifically assessing GV are lacking. Furthermore, 
studies in heart transplantation suggested that mTOR in-
hibitors could prove beneficial in preventing GV [159, 
160]. In clinical VCA, the significance of mTOR inhibi-
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tors is still unclear. Reports of a face and hand recipient 
suggest that the use of mTOR inhibitors could not pre-
vent changes resembling chronic rejection and GV [2, 
96]. Second, cell-based therapies could help reduce GV. 
In a humanized mouse model, two distinct populations 
of expanded regulatory T cells were utilized for this pur-
pose [161]. The authors found that both CD127-positive 
and -negative regulatory T cell-expanded populations 
administered systemically immediately after transplan-
tation were capable of inhibiting intimal hyperplasia and 
GV [161]. The immunomodulatory potential of mesen-
chymal stem cells is also in the spotlight for VCA in terms 
of increasing graft acceptance [162–165]. Mesenchymal 
stem cells are known to reduce endothelial activation 
[166] and to attenuate inflammatory intimal thickening 
in rodent arteries [167]. Recently, our group has shown 
in a rat hindlimb transplant model that repetitive admin-
istration of adipose-derived mesenchymal stem cells in 
the first 2 weeks after transplantation drastically reduced 
intimal thickening in large vessels of long-term surviving 
animals [168].
Additional potential therapeutic strategies against GV 
may include optimized preservation systems. Machine 
perfusion is superior to cold storage, with improved sur-
vival and function of the transplanted grafts in SOT [169, 
170], and a similar effect might be expected for VCA. In-
deed, Werner et al. [57] showed that 24 h of ex vivo per-
fusion of human limbs preserved neuromuscular func-
tion. In terms of minimizing IRI and its associated vascu-
lar damage, a variety of additives to the current cold 
storage solutions could be beneficial [171]. In this con-
text, polyethylene glycol, hydroxide sulfide, and simvas-
tatin seem promising [65, 66, 172]. Additionally, enteral 
as well as parenteral administration of simvastatin may 
have an alleviating effect on IRI. A study by Zhao et al. 
[173] in a mouse hindlimb ischemic model showed that 
intraperitoneal administration of simvastatin parallel to 
ischemic insult of 2 h followed by reperfusion can reduce 
IRI by reduction of cytokine formation, downregulating 
adhesion molecule expression and reducing leukocyte ac-
cumulation. In a setting of rat cardiac transplantation, the 
work by Tuuminen et al. [174] provided evidence that 
donor oral pretreatment with simvastatin could counter-
act IRI, endothelial dysfunction, and chronic rejection.
In summary, there is no clinically applicable causal 
treatment of transplant vasculopathy in VCA to date. The 
first chronic graft failure in a face transplant patient could 
not be reversed [2] and underscores the serious threat of 
chronic rejection and GV for VCA [175]. To our best 
knowledge, prevention seems to be the best strategy.
Conclusions and Outlook
GV appears to be a multifactorial entity shared be-
tween acute and chronic rejection. However, the true 
mechanisms of GV are unknown and with good long-
term results in many VCA patients without GV, the ex-
act mechanisms have still to be elucidated. Advances 
made in reconstructive transplantation over the last 
two decades in both peri- and postoperative manage-
ment allowed for very satisfying short- and mid-term 
results, which, however, were short-lived in some pa-
tients owing to progressive long-term graft deteriora-
tion. Chronic rejection and GV are often referred to as 
similar phenomena, but with the current state of knowl-
edge and in light of different pathophysiological path-
ways potentially resulting in vascular changes, their re-
lationship and shared characteristics remain to be clar-
ified.
Proper diagnostic markers and tools must be imple-
mented to detect GV in the early phase, and the exact un-
derlying pathways need to be better understood to evalu-
ate novel drug- and cell-based therapies for the preven-
tion, attenuation, or reversal of GV.
Although limited to a low number of cases, the strong 
association of class II de novo DSA with AMR, GV, and 
ultimately allograft loss calls for attention. If AMR is sus-
pected, deep tissue biopsy should be favored since stan-
dard skin biopsy might not be sufficient for diagnosis of 
GV. Accordingly, with the aim of stopping progression of 
GV at an early stage, the threshold for antibody-targeted 
therapies during suspected AMR should be lowered, even 
in the absence of strong clinical signs of rejection.
Noninvasive diagnostic tools such as UBM are gain-
ing relevance in VCA because they allow for repetitive 
monitoring of the zone of interest without morbidity, 
but these applications are in their infancy and need to be 
further evaluated. Detection of GV by peripheral blood 
gene or marker analysis are additional promising alter-
natives.
At present, the best “therapy” for multifactorial GV is, 
perhaps, prevention. Evidence points at better outcomes 
and reduced GV by reducing IRI through optimized pres-
ervation protocols, concomitant cell therapies, and novel 
drug-based induction therapies, or a combination of all 
three.
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